Domino’s Pizza Australia rejects Bain Capital takeover report after share surge
Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced on Friday that it has filed a prospectus supplement to increase the aggregate offering price of its common stock shares under its existing At The Market Offering Agreement with H.C. Wainwright & Co., originally dated February 14, 2025. The company’s common stock has a par value of $0.0001 per share and is listed on The NASDAQ Stock Market LLC.
The filing also includes an opinion from Ellenoff Grossman & Schole LLP regarding the legality of the issuance and sale of the shares. According to the statement, this action was disclosed in a press release and detailed in an SEC filing.
No additional financial terms, such as the new aggregate offering price or the number of shares to be issued, were specified in the filing.
In other recent news, Vivos Therapeutics Inc. reported its second-quarter 2025 earnings, which revealed a larger-than-expected loss per share. The company announced an earnings per share (EPS) of -$0.55, missing analysts’ forecast of -$0.39 by 41.03%. Despite the earnings miss, Vivos Therapeutics’ revenue slightly exceeded expectations, reaching $3.8 million compared to the forecasted $3.78 million. Additionally, a new clinical trial published in the European Journal of Pediatrics highlighted the effectiveness of Vivos’ DNA appliance for treating obstructive sleep apnea in children. The study found that 77% of pediatric participants experienced at least a 50% reduction in the severity of their condition. These developments come as part of the company’s efforts to expand its Complete Airway Repositioning and Expansion (C.A.R.E.) line of devices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.